Results 161 to 170 of about 23,792 (240)
Cancer risk due to type 2 diabetes [PDF]
, 2017 Epidemiologic studies show that type 2 diabetes increases the risk of certain cancers. Different antidiabetic drugs used for the treatment of type 2 diabetes can modify cancer risk.
Albert, A. +3 more
core
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 840-849, February 2026.Abstract Continuous glucose monitoring (CGM) has emerged as a complementary and more dynamic method for evaluating glycemic control in people with diabetes. Relevant studies examining the association between CGM parameters, including time in range (TIR), glycemic variability (GV), and time in tight range (TITR), and diabetic nephropathy, retinopathy ...
Lilian Anagnostopoulou +4 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo +8 more
wiley +1 more source
Spotlight commentary—Insulin therapy: Future directions
British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 351-353, February 2026.
Ana Deškin +4 more
wiley +1 more source
Sensory network dysregulation in type 2 diabetes: Linking olfactory, visual, and cognitive function
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1234-1246, February 2026.Abstract Aims This study investigates the relationship between multisensory (visual, somatosensory, and olfactory) dysfunction and cognitive decline in Type 2 diabetes (T2D), with a particular focus on the mediating role of olfactory dysfunction. Methods We used resting‐state fMRI to assess seed‐based functional connectivity from the primary sensory ...
Qian Li +12 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1304-1314, February 2026.Abstract Aim PIONEER REAL Saudi Arabia investigated real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes (T2D). Materials and Methods This was a 34‐ to 44‐week multicentre, prospective, open‐label study in adults with T2D, who were treatment‐naive to injectable glucose‐lowering medication ...
Hussein ElBadawi +11 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1508-1516, February 2026.Abstract Aims Ramadan fasting poses challenges for patients with type 2 diabetes mellitus (T2DM) due to increased risks of hypoglycemia and metabolic fluctuations. Tirzepatide, a dual GIP/GLP‐1 receptor agonist, has shown marked efficacy in glycemic control and weight reduction.
Muhammad Hafizur Rahman +11 more
wiley +1 more source
Journal of Diabetes Investigation, Volume 17, Issue 2, Page 205-213, February 2026.Orforglipron, a novel oral non‐peptide GLP‐1 receptor agonist, was evaluated in a Phase 1, double‐blind, placebo‐controlled, randomized, single and multiple ascending dose study in Japanese participants with type 2 diabetes. The safety and tolerability profile of orforglipron was consistent with those of other GLP‐1 receptor agonists, and ...
Kenji Ohwaki +4 more
wiley +1 more source
Insulinoma presenting with postprandial hypoglycemia and a low body mass index: A case report. [PDF]
World J Clin Cases, 2020 Prídavková D +6 more
europepmc +1 more source
Journal of Diabetes Investigation, Volume 17, Issue 2, Page 366-370, February 2026.Dapagliflozin improved glycemic control and insulin resistance while preserving skeletal muscle mass, body weight, and renal function over 2 years in a patient with Werner syndrome. These findings suggest that SGLT2 inhibitors may be used safely with beneficial effects in patients with Werner syndrome.
Takashi Yagi +7 more
wiley +1 more source